Goodchild Investments Pty Ltd

Drawbridge Pharmaceuticals Pty Ltd

Juliet M Goodchild

Colin Stanley Goodchild

Colin S Goodchild

The present disclosure teaches generally neuroprotection and in particular the use of non-hormonal neuroactive steroids to ameliorate inflammation of the central nervous system (CNS). More specifically, the present claims define methods of treating inflammation or ameliorating a neuroinflammatory-promoting condition in the CNS by administration of a steroid with certain properties formulated in a sulfobutyl ether beta-cyclodextrin composition. The steroid is neuroactive, devoid of hormonal endocrine activity and activates a pregnane X receptor. Examples of such steroids include alphaxalone, alphadolone allopregnanolone, pregnanolone, ganaxolone, hydroxydione, minaxolone, Org20599, Org21465, CT1341 and compounds of Formula (I). Dependent claims further define the type of the neuroinflammatory-promoting conditions, the type of cyclodextrin, the molar ratio of neuroactive steroid to the cyclodextrin and the inclusion of other active agents or excipients in the composition and their nature. 

Growing community of inventors

Melbourne, Australia

Juliet M Goodchild